Introduction
There are generally two stages regarding early embryonic hematopoiesis in the mouse.
The first stage, the primitive hematopoiesis, is characterized by de novo generation of nucleated erythrocytes (large and production of embryonic hemoglobin) in the extraembryonic yolk sac (YS). The second stage, the definitive hematopoiesis, is marked by autonomous formation of adult type hematopoietic stem cells (HSCs) in E10.5 major vessels or highly vascularized structures, i.e. the aorta-gonad-mesonephros (AGM) region, umbilical/vitelline arteries, YS, and placenta (1) (2) (3) (4) (5) (6) (7) (8) . Both stages, though largely differential in hematopoietic activities, closely intertwine with vascular lineage in two speculated forms: the hemangioblast (a common precursor for hematopoietic and endothelial lineages) and the hemogenic endothelium (dedifferentiation of mature endothelium into hematopoietic lineage) (9) (10) (11) (12) .
Eighty years ago, the term of hemangioblast was proposed by the finding that, in the YS, the aggregated mesodermal cells simultaneously gave rise to central primitive erythrocytes and peripheral endothelial cells in close proximity, forming a distinct structure called blood island. It was until 1998 that two independent groups provided the first convincing evidence of hemangioblast by in vitro differentiation assay of mouse embryonic stem cells (ES cells). Nishikawa et al. utilized collagen-based 2 dimensional differentiation system with OP9 feeder layer to visualize the blood budding and the tube formation from single Flk-1 + CD144 + cells (13) . Alternatively, Choi et al. defined the clonal blast colony-forming cells (BL-CFCs) with remarkable VEGF responsiveness in early embryoid bodies (EB) (14) . Recently, they revealed that the comparable BL-CFC (Brachyury + Flk-1 + ) predominantly arose at the posterior primitive streak of E7.5 embryos, contrary to the presumed YS (15) . Such a finding suggests that 1) the precursor represents a transient mesoderm population undergoing hematopoietic and vascular specification, and 2) hematopoietic commitment initiates prior to the establishment of YS blood island. It is believed that the ES cell-derived hematopoietic differentiation recapitulates the YS-stage hematopoiesis (16) . Up to date, the ES cell/hemangioblast models are instrumental to understand complicated molecular mechanisms underlying the mesoderm-hemangioblast-hematopoietic commitment cascade. In comparison, the hemangioblastic origin and molecular modulation of intra-embryonic definitive hematopoiesis remain poorly understood. Because the AGM region-derived HSCs possess nearly all the immunophenotypic features of endothelium (LDL receptor + , CD31 + , CD144 + , CD34 + and Tie2 + ), it is accepted that the hemogenic endothelium serves as the direct precursor of HSC (17) (18) (19) (20) . Recently, we found that the high proliferation potential precursors in the mouse AGM region could be categorized into 2 types: one restricted to hematopoietic lineage, and the other with hemangioblastic properties (refereed to be HPP-HA) (21) . Of note, whether hemangioblasts (from either ES cells or embryos)
possess lymphoid potential remains unknown.
Here, we combine the BL-CFC and the OP9 systems to quantify hemangioblast with B and T lymphoid potential in the mouse AGM region. Screening of candidate cytokines reveals interleukin-3 (IL-3) a positive regulator of hemangioblast development in the AGM region.
Design and methods

Embryo dissections
C57BL/6 mice were mated overnight. Noon of the day when a vaginal plug was detected was designated as E0. 5 . At the time point as indicated, mice were killed, and embryos were dissected free of decidual tissues and Reichter's membrane. Somite-stage embryos were staged by counting somite numbers. The embryonic tissues were treated with 0.1% type I collagenase (Sigma, St. Louis, MO) at 37°C for 1 hour (for the AGM region, placenta and YS) or 1-1.5 hours (for E7.5 embryos), and then dispersed into single-cell suspension. Cell counts and viability were estimated by trypan blue exclusion.
BL-CFC and hematopoietic CFC assay
BL-CFC media was composed of 0.9% methylcellulose (Sigma), 2 mM glutamine (Hyclone, Logan, Utah), 100U/ml;100!g/ml penicillin/streptomycin (Hyclone), 5% proteinfree hybridoma medium II (Gibco, Grand Island, NY), 200 !g/ml iron-saturated transferrin (Sigma), 1% BSA (Stem Cell Technologies, Vancouver, Canada), 0.45 mM monothioglycerol (MTG, Sigma), 15% FBS (Hyclone) and a cytokine cocktail including rhbFGF (10 ng/ml), rmSCF (50 ng/ml), rhIL-6 (5 ng/ml), rhIGF-I (50 ng/ml), rmLIF (10 3 U/ml) and rhVEGF-165 (5 ng/ml). Following 4-5 days of inoculation, blast colonies were scored. For hematopoietic CFC assay, cytokine cocktail included rmSCF (50 ng/ml), rmIL-3 (10 ng/ml), rhIL-6 (5 ng/ml), rhIL-11 (10 ng/ml), rmGM-CSF (10 ng/ml), rhTpo (20 ng/ml), rhEpo (3 U/ml). Primitive hematopoietic colonies were scored at day 4 to 7 of culture, whereas definitive erythroid colonies were counted after 3 to 5 days of incubation. CFU-GM, BFU-E and CFU-Mix were counted after 7 to 10 days of culture.
In vitro tube formation assay
Individual blast colonies were plucked and transferred to single wells of 96-well plates containing IMDM with 10% FBS, 10% horse serum, rhbFGF (10 ng/ml), rhVEGF-165 (5 ng/ml), rhIGF-I (10 ng/ml), rmSCF (50 ng/ml), rmIL-3 (10 ng/ml), rhIL-11 (10 ng/ml), rhEpo (3 U/ml) ,ECGS(100!g/ml), L-glutamine (2 mM) and 0.45 mM MTG. After 4 days of incubation, nonadherent cells were removed and the adherent cells were inoculated with endothelial growth medium-2 (EGM2, Cambrex, Walkersville, MD) for further 6 days. 
OP9-based hematopoietic and endothelial progenitor potential assay
Individual blast colonies were plated on the OP9 stromal cells in the presence of VEGF (200 ng/ml), FL (20 ng/ml) and IL-7 (20 ng/ml). After 10 days of culture, they were fixed in 4% paraformaldehyde for 30 minutes, and were incubated with monoclonal antibody against CD45 (PE-conjugated, eBioscience, San Diego, CA) overnight at 4°C. Thereafter, a two-step staining protocol was used to identify the endothelial development. Following a primary anti-CD31 antibody (BD Pharmingen) incubation, the culture was visualized by the indirect immunoperoxidase method using horseradish peroxidase-conjugated anti-rat IgG (Zymed, South San Francisco, CA, USA). The peroxidase activity was visualized using 3,38-diaminobenzidine (Zymed).
To determine B lymphoid potential, blast colonies were replated on fresh OP9
stromal cells in the presence of FL (20 ng/ml) and IL-7 (20 ng/ml). After 7-10 days of culture, B lymphocyte differentiation was assessed.
To generate T lymphocytes, blast colonies were replated onto OP9-DL1 stromal cells supplemented with FL (5 ng/ml), IL-7 (5 ng/ml) and TPO (5 ng/ml). After 4 days of culture, TPO were withdrawn. T lymphocyte differentiation was analyzed after further 11- 
Magnetic sorting
Single-cell suspension from AGM region was labeled with purified anti-mouse CD31 (BD Pharmingen), Endomucin, biotin-conjugated CD105 (Endoglin) or PDGFRß monoclonal antibodies (eBioscience), followed by incubating with anti-rat or anti-biotin microbeads.
Magnetic sorting was performed according to the manufacture's protocol and processed through an MS-separation column attached to a Mini-MACS separation unit (Miltenyi Biotech).
Nested RT-PCR, RT-PCR and real-time PCR
Nested RT-PCR for individual colonies was performed as described previously (21) . For
RT-PCR analysis, total RNA from E7.5 embryos or E10.5 AGM region were extracted using TRIZOL reagent (Invitrogen) and reverse transcribed using mRNA Selective PCR Kit (TaKaRa). Blast colonies were harvested and analyzed by quantitative real-time PCR as described previously (22) . The specific primer sequences and amplified product size are listed in Table S1 to S3 respectively.
Immunofluorescence staining
Blast colony cells were stained with monoclonal antibodies against Sca-1 (PE- 
Immunohistochemistry
Immunohistochemistry was performed as described previously (22) . The primary antibodies used were as follows: anti-CD31, anti-Endomucin, and anti-PDGFR! (Cell Singaling).
Western blotting
Total proteins of AGM cells were harvested. 60 micrograms of proteins were loaded on 12% SDS-PAGE. Immunoblotting was performed using anti-Stat5, anti-Phospho-Stat5, anti-Erk1/2, anti-Phospho-Erk1/2 and anti-Actin antibodies (Cell Signaling Technology, Danvers, MA) according to the manufacturer's instructions.
Other reagents
Oncostatin M (OSM) was obtained from R&D Systems (Minneapolis, MN, USA). IL-3-blocking antibody and IgG1 were purchased from BD PharMingen (San Diego, CA, USA). The MEK1/2 inhibitor PD98059 was purchased from Promega (Madison, WI, USA) and the JAK2 inhibitor AG490 from Sigma.
Phase contrast and fluorescence imaging
Phase contrast images were collected by using a Nikon TE2000-U (Tokyo, Japan) 
Statistical analysis
The results were expressed as the means ± s.e.m. Significance is determined using the Student's t-test: *, P<0.05; **, P<0.01, compared with the control data.
Results
Characterization of BL-CFC in the mouse AGM region
To fulfill clonal BL-CFC analysis, single-cell suspension from mouse E10.5 AGM region (0.5-1x10 5 cells/ml) was plated in methylcellulose media containing bFGF, SCF, VEGF, LIF, IGF-I and IL-6. After 4-5 days of incubation, the typical blast colonies with unique and identifiable morphology emerged. The blast colony was composed of a compact core and a loose peripheral layer with clear intercellular boundaries (Fig. 1A ). Under such a condition, the typical hematopoietic colonies were rare and could be easily identified. 1C ). The data suggested that the AGM region-derived blast colonies progressed beyond the mesoderm and underwent hemangioblastic commitment.
Then we attempted to determine the critical cytokines for generating the blast colonies from the AGM region. By eliminating a cytokine from the original formula (SCF+bFGF+IL-6+IGF-I+LIF+VEGF) one by one, we found that bFGF and SCF had the strongest effect on colony growth (p<0.01). The removal of IL-6 had a modest effect on the number of colonies (p<0.05) (Fig. S1 ).
To validate the hematopoietic potential, the blast colonies were individually harvested and replated into hematopoietic CFC system containing SCF, IL-3, IL-6, IL-11, Epo, TPO and GM-CSF. As demonstrated in Fig. 1D , they gave rise to CFU-E, CFU-GM, CFU-Mix, and BFU-E. Of 12 representative colonies, all could generate hematopoietic CFCs (Fig. 1E ). On average, a single BL-CFC yielded 5.7 CFU-E, 1.9 CFU-GM, and 5.7
CFU-Mix.
To further identify the vascular potential, a single blast colony was cultured in a liquid expansion system with hematopoietic and endothelial cytokines (bFGF, VEGF, SCF, IL-3, IL-11, Epo, IGF-I and ECGS). After 24h of incubation, the adherent cells were evident in over 97% (64/66) colonies. In a couple of days, they amplified significantly ( OP9, the bone marrow stromal cell line, is known to provide appropriate microenvironment for endothelial and lymphocyte differentiation (13, 23, 24) . To further validate the hemangioblastic activity, 50 blast colonies were individually co-cultured with OP9 cells for 10 days. All of them demonstrated both hematopoietic and endothelial progenitor potential. As shown in Fig. 2A, 4 representative colonies simultaneously generated abundant CD45 + hematopoietic cells and CD31 + tube-like structures on OP9 stromal cells.
To determine B lymphoid potential, blast colonies were incubated with OP9 in the presence of FL and IL-7 for 7-10 days. After 6 days of culture, significant proliferation of round non-adherent cells was detected (Fig. 2B ). B220 (CD45R) is expressed at all stages of B-cell ontogeny. However, CD19 remains the most reliable marker for Blineage commitment. As shown in Figure 2C , abundant B220 + and CD19 + populations were generated from blast colonies. Mature B cells were detected in approximately 1.5%
of total cells by analyzing surface expression of IgM.
To further assay T lymphoid potential, blast colonies were co-cultured with OP9-DL1 cells (proven to support T lymphocyte development from hematopoietic stem progenitor cells and ES cells) (24, 25) . After 8 days of culture, round non-adherent cells proliferated abundantly (Fig. 2D) . After 15-20 days, the CD3 + TCR_ + and CD4 + /CD8 + T lymphocytes were generated (Fig. 2E) . Also, NK1. (Table S4) . Compared with the OP9 co-culture, differentiation of CD19 + B lymphocytes was greatly suppressed in the OP9-DL1 system (data not shown).
Therefore, the blast colonies contained hematopoietic precursors with both myeloid and lymphoid potential, indicating the definitive hematopoietic identity.
As previously described (14, 15) , two steps were taken to validate the clonality of the AGM-derived blast colonies. First, cells from the AGM region were plated at different concentrations. As shown in Fig. 3A , the number of blast colonies was directly proportional to that of AGM cells input, indicating that a single cell corresponded to the growth of a colony. Second, the cell mixing analysis was carried out (Fig. 3B ). An equal number of cells from the AGM region of male wild type (Sry + GFP -) and female GFP transgenic (Sry -GFP + ) mice were mixed at the density of 0.5-1x10 5 cells/ml. After 4 days of culture, the blast colonies were picked out and expanded individually to determine the content of genomic DNA. Among 20 representative colonies analyzed, 10 displayed exclusively Sry + GFP -genotype and the rest 10 Sry -GFP + (Fig. 3B) . Representative blast colonies from wild type and GFP transgenic AGM region in the cell mixing analysis were shown in Fig. 3C . Therefore, the experiments suggested that the blast colony originated from a single cell.
Spatiotemporal distribution and surface markers of BL-CFC in the mouse AGM region
To characterize the developmental kinetics of BL-CFC in the caudal half (E9.5) or AGM region (E10.5-12.5), the tissues were analyzed daily between E9.5 and E12. Next, four molecules were selected to determine the location of BL-CFC in the AGM region. As shown in Fig. 4B , C and previous reports (26, 27) , CD31, Endomucin, and CD105 had similar expression pattern (restricted to the endothelial layers and intro-aortic hematopoietic clusters). In contrast, PDGFR_ is expressed by mural cells (Fig. 4D) , and its response to PDGF secreted by endothelial cells results in migration and maturation of mural cells (28) . As demonstrated in Fig. 4E -G, the E10.5 AGM-derived BL-CFCs were enriched by CD31, Endomucin, and CD105 exclusively. Together with the finding that most of BL-CFCs were negative for PDGFR_ (Fig. 4H) , we concluded that the hemangioblasts were mainly located within the endothelium lining the vessel wall of dorsal aorta.
Of note, the blast colonies were not readily detected in cells from yolk sac (E9.5-E11.5), placenta (E9.5-E11.5), fetal liver (E10.5-E11.5) and embryonic circulation (E10.5-E12.5) (Fig. 4I) .
Positive regulation of AGM-derived BL-CFC by IL-3
As the BL-CFC model was quantitative, a set of hematopoietic/vascular cytokines (i.e., bFGF, SCF, GM-CSF, IL-6, OSM, VEGF, TPO, IL-3, EPO) were screened for their modulation on the hemangioblast development in the mouse AGM region. Initially, singlecell suspension of the AGM region was incubated with indicated cytokines for 12h, and then collected for the BL-CFC assay. As anticipated, a significant expansion of BL-CFC was detected in the presence of bFGF (10 ng/ml). However, among other cytokines, only IL-3 (50 ng/ml) could remarkably amplify the BL-CFC (148.0±22.5 Vs 46.7±8.6, p<0.01) and the effect appeared more profound than bFGF (Fig. 5A) . Interestingly, IL-3-stimulated BL-CFCs formed typical blast colonies at day 2.5 of culture, 12h earlier than the control. Furthermore, the effect was dose dependent ( and MAPK/ERK signaling (Fig. 5F ).
Increased hematopoietic and vascular potential of IL-3-treated BL-CFC
We carried out differentiation assay to determine the regulatory roles of IL-3 in the hematopoietic/vascular potential of BL-CFCs. As shown in (Fig. 6B-D) . Alternatively, IL-3 was added during the formation of blast colonies. As shown in Fig.6E , the IL-3-treated blast colonies generated increased number of CD31 + tubes on OP9 stromal cells, confirming the enhanced endothelial progenitor capacity.
Subsequently, several hematopoietic-and vascular-related genes were selected to define the IL-3-mediated molecular changes in the AGM cells. Upon stimulation, upregulated expression of Scl and vWF were detected, corroborating the enhanced hematopoiesis and endothelial differentiation in BL-CFC assay (Fig. 6F) . Of interest, expression of Runx1 was significantly decreased, presumably reflecting its complicated and dose-dependent involvement in regulating embryonic hematopoiesis.
These data collectively indicated that incubation with IL-3 led to elevated number as well as intrinsic hemangiopoietic commitment of the hemangioblast.
IL-3 promoted primitive hematopoiesis in E7.5 embryos
The first wave of hemangioblast (BL-CFC) is detected mainly in posterior primitive streak of E7.5 embryos. Of note, the number of BL-CFC in this stage is small, and the hypoxia culture condition is critical. We only detected typical hematopoietic other than BL-CFC colonies in E7.5 embryos. Once transferred to the liquid expansion media, these hematopoietic-like colonies remained non-adherent and failed to expand as adherent population. As shown in arterial specification (62) . Taken together, these data suggest that IL-3 can exert functions on the hemangiopoietic system from active embryogenesis to homeostatic adulthood.
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